Fri, 08 May 2009 15:20:16 -0400 PeerView Hematology CME/CNE/CPE Video Podcast PeerView Press http://www.peerviewpress.com Podcast Maker v1.3.8b - http://www.lemonzdream.com/podcastmaker Thought leader perspectives on current clinical advances in medicine PeerView Press is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. en 2007 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://podcast.peerviewpress.com/videohematologyus/vidHematologyCME-CNE-CPE_144.jpg PeerView Hematology CME/CNE/CPE Video Podcast http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Hematology no Richard M. Stone, MD - Exploring New Trends in MDS & AML: From Clinical Data in Poor-Prognosis Patients to Mechanisms of Novel Agents PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Experts in MDS and AML discuss the clinical importance of new findings in these settings, specifically the following topics: an evaluation of modified induction/consolidation chemotherapy in AML, an update on epigenetic treatment and the potential of epigenetic combinations to augment activity in MDS and AML, and the relevance of newer prognostic models to a well-rounded clinical approach. Faculty will also discuss new data on the mechanisms of epigenetic agents, and whether these data possess prognostic or predictive implications. http://podcast.peerviewpress.com/videohematologyus/PA05351FCs514.m4v http://podcast.peerviewpress.com/videohematologyus/PA05351FCs514.m4v Tue, 03 Mar 2009 15:09:44 -0500 Science, Medicine no 00:40:26 MDS, AML, hematologic malignancies, ASH 2008, methylation, HDAC inhibitors, epigenetics CME/CNE/CPE Information - Exploring New Trends in MDS & AML: From Clinical Data in Poor-Prognosis Patients to Mechanisms of Novel Agents PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/videohematologyus/PA05351FCCMEinfo.pdf http://podcast.peerviewpress.com/videohematologyus/PA05351FCCMEinfo.pdf Tue, 03 Mar 2009 15:09:42 -0500 Science, Medicine no 00:00:00 MDS, AML, hematologic malignancies, ASH 2008, methylation, HDAC inhibitors, epigenetics Jorge Cortes, MD - Maximizing Outcomes in CML Throughout the Treatment Continuum PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, a leading hematologist-oncologist will lead participants through 2 case scenarios in diverse CML settings and illustrate important aspects of disease management. The first case will detail appropriate therapy selection in a newly diagnosed patient with CML and consider the nuances of patient care at various time points to illustrate proper long-term treatment and other issues, including safety related to the extended use of tyrosine kinase inhibitor therapy. The second case will focus on the second-line CML setting, and develop an interactive scenario centered on therapeutic decision points, including appropriate agent selection in the face of specific mutational status or patient characteristics with implications for safe administration of therapy. http://podcast.peerviewpress.com/videohematologyus/PA05123FCp150.m4v http://podcast.peerviewpress.com/videohematologyus/PA05123FCp150.m4v Wed, 26 Nov 2008 11:31:23 -0500 Science & Medicine no 00:22:37 imatinib, nilotinib, dasatinib, TKI, CML, growth-factor support, hematologic reponse, CCyR, MMR CME/CE Information - Maximizing Outcomes in CML Throughout the Treatment Continuum PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/videohematologyus/PA05123FCCMEinfo.pdf http://podcast.peerviewpress.com/videohematologyus/PA05123FCCMEinfo.pdf Wed, 26 Nov 2008 11:30:53 -0500 Science & Medicine no 00:00:00 imatinib, nilotinib, dasatinib, TKI, CML, growth-factor support, hematologic reponse, CCyR, MMR William Bensinger, MD - Therapeutic Options for Transplant- and Non-Transplant-Eligible Patients With Multiple Myeloma: A Clinical Update PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in hematology discuss latest clinical advances in the treatment of multiple myeloma. http://podcast.peerviewpress.com/videohematologyus/PA04421FCr392.m4v http://podcast.peerviewpress.com/videohematologyus/PA04421FCr392.m4v Thu, 04 Sep 2008 16:42:28 -0400 Science & Medicine no 00:46:31 Multiple myeloma, melphalan, alkylators, thalidomide, bortezomib, lenalidomide, dexamethasone, thrombosis, proteasome inhibitor, carfilzomib CME/CE Information - Therapeutic Options for Transplant- and Non-Transplant-Eligible Patients With Multiple Myeloma: A Clinical Update PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/videohematologyus/PA04421FCCMEinfo.pdf http://podcast.peerviewpress.com/videohematologyus/PA04421FCCMEInfo.pdf Thu, 04 Sep 2008 16:41:28 -0400 Science & Medicine no 00:00:00 Multiple myeloma, melphalan, alkylators, thalidomide, bortezomib, lenalidomide, dexamethasone, thrombosis, proteasome inhibitor, carfilzomib Moshe Talpaz, MD - CML Controversial Issues: Debating the Use of Molecular Monitoring and Potential for Individualized Therapy PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts provide an update on treatment resistance in CML. Definitions, prevalence, and mechanisms of resistance are reviewed, the benefits and limitations of using molecular monitoring in the clinical management of CML are assessed, strategies for selecting optimal targeted therapy to circumvent or overcome treatment resistance are debated, and the potential for tailoring tyrosine kinase therapy according to individual patient or disease characteristics, including BCR-ABL mutations, is discussed. http://podcast.peerviewpress.com/videohematologyus/PA04328FCe015.m4v http://podcast.peerviewpress.com/videohematologyus/PA04328FCe015.m4v Thu, 21 Aug 2008 09:53:41 -0400 Science & Medicine no 00:41:40 CML, chronic myelogenous leukemia, BCR-ABL, molecular monitoring, imatinib, dasatinib, resistance, TKI CME/CE Information - CML Controversial Issues: Debating the Use of Molecular Monitoring and Potential for Individualized Therapy PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/videohematologyus/PA04328FCCMEinfo.pdf http://podcast.peerviewpress.com/videohematologyus/PA04328FCCMEinfo.pdf Thu, 21 Aug 2008 09:48:30 -0400 Science & Medicine no 00:00:00 CML, chronic myelogenous leukemia, BCR-ABL, molecular monitoring, imatinib, dasatinib, resistance, TKI Guillermo Garcia-Manero, MD - Epigenetic Alterations as Targets of Therapy in Myelodysplastic Syndromes: Applying Science to Clinical Practice PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this program, an expert will discuss the concept of epigenetics and targets of epigenetic therapy in myelodysplastic syndromes (MDS). Recent data on efficacy and safety of novel DNA hypomethylating agents in the treatment of MDS are also reviewed, as well as the implications of these data for clinical practice and research. http://podcast.peerviewpress.com/videohematologyus/PA04356FCr372.m4v http://podcast.peerviewpress.com/videohematologyus/PA04356FCr372.m4v Mon, 12 May 2008 14:31:22 -0400 Science & Medicine no 00:34:11 Epigenetics, DNA hypomethylating agents, 5-azacitidine, decitabine, growth-factor support, dosing regimens, combination regimens, toxicity, myelosuppression, thrombocytopenia, neutropenia CME/CE Info - Epigenetic Alterations as Targets of Therapy in Myelodysplastic Syndromes: Applying Science to Clinical Practice PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/videohematologyus/PA04356FCCMEinfo.pdf http://podcast.peerviewpress.com/videohematologyus/PA04356FCCMEinfo.pdf Mon, 12 May 2008 14:30:24 -0400 Science & Medicine no 00:00:00 Epigenetics, DNA hypomethylating agents, 5-azacitidine, decitabine, growth-factor support, dosing regimens, combination regimens, toxicity, myelosuppression, thrombocytopenia, neutropenia Jamile M. Shammo, MD, FASCP - State of the Science in MDS: Update on Diagnosis, Evaluation, and Treatment PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this program, MDS experts present an update on disease classification and review new data on current and emerging treatment options. http://podcast.peerviewpress.com/videohematologyus/PA04297FCr364.m4v http://podcast.peerviewpress.com/videohematologyus/PA04297FCr364.m4v Thu, 28 Feb 2008 16:31:07 -0500 Science & Medicine no 00:37:54 acute myeloid leukemia, AMG 531, AML, American Society of Hematology, anemia, ASH, azacitidine, clofarabine, cytarabine, cytogenetic testing, decitabine, deferasirox, deletion 5q, etanercept, FAB classification, homoharringtonine, IPSS, iron chelation CME/CE Information - State of the Science in MDS: Update on Diagnosis, Evaluation, and Treatment PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/videohematologyus/PA04297FCCMEinfo.pdf http://podcast.peerviewpress.com/videohematologyus/PA04297FCCMEinfo.pdf Thu, 28 Feb 2008 16:31:04 -0500 Science & Medicine no 00:00:00 acute myeloid leukemia, AMG 531, AML, American Society of Hematology, anemia, ASH, azacitidine, clofarabine, cytarabine, cytogenetic testing, decitabine, deferasirox, deletion 5q, etanercept, FAB classification, homoharringtonine, IPSS, iron chelation Aryeh Shander, MD - Anemia Management and Blood Conservation in the Hospital Setting PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, physicians who are expert in the management of anemia and the use of blood products discuss the efficacy and risks of RBC transfusion and alternative strategies for the management of anemia in the critically ill, including the use of erythropoiesis-stimulating agents. http://podcast.peerviewpress.com/videohematologyus/PA03696FCr324.m4v http://podcast.peerviewpress.com/videohematologyus/PA03696FCr324.m4v Tue, 24 Jul 2007 09:50:40 -0400 Science & Medicine no 00:36:54 Anemia, Blood conservation, Critical care, Erythropoietin, Transfusion CME/CE Information - Anemia Management and Blood Conservation in the Hospital Setting PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/videohematologyus/PA03696FCCMEinfo.pdf http://podcast.peerviewpress.com/videohematologyus/PA03696FCCMEinfo.pdf Tue, 24 Jul 2007 09:50:15 -0400 Science & Medicine no 00:00:00 Anemia, Blood conservation, Critical care, Erythropoietin, Transfusion